Norway· NO-ID_AD9F0868-34B4-4BAF-BA82-29A6A45F74CF
Pegasys
A peginterferon alfa-2a product containing peginterferon alfa-2a, registered in Norway by pharmaand GmbH. The same ATC class is registered in 14 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Peginterferon alfa-2a is registered in 14 of 19 countries.
Countries holding a registration under ATC L03AB11 (peginterferon alfa-2a), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Peginterferon alfa-2a · ATC L03AB11
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Peginterferon Alfa-2a
- Manufacturer
- pharmaand GmbH
- Country
- Norway (NO)
- ATC code
- L03AB11
- ATC class
- Peginterferon alfa-2a
- Defined daily dose
- 26 mcg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_AD9F0868-34B4-4BAF-BA82-29A6A45F74CF
- no_varenummer0087824 x 0.5NOK 8697.4
- gtin9120099674218
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
201 interactions on record for peginterferon alfa-2a.
Graded by severity as the source publishes them — 35 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Peginterferon alfa-2a · interactions on record
201 records
- 35 severe
- 163 moderate
- 3 minor
Most severe, free to view
- EltrombopagB02BX05severe
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- TelbivudineJ05AF11severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Peginterferon alfa-2a in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPEGASYSpharmaand GmbH, Vienna
- BelgiumPegasys 180 µgpharmaand
- SpainPEGASYS 180 microgramos SOLUCION INYECTABLE EN PLUMA PRECARGADAZr Pharma & Gmbh
- SwedenPegasys 180 mikrogram Injektionsvätska, lösningpharmaand GmbH
- United KingdomPegasys 90micrograms/0.5ml solution for injection pre-filled syringespharmaand GmbH
- FinlandPegasysOrifarm Oy
- United StatesPegasyspharmaand GmbH
- PolandPegasyspharmaand GmbH
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Pegasys
- Liechtenstein · Pegasys
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fa49aea4-a200-4d3f-9a23-d15835ffb077 GET /v1/drugs/fa49aea4-a200-4d3f-9a23-d15835ffb077?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Peginterferon alfa-2a",
"merkevare_id": "ID_AD9F0868-34B4-4BAF-BA82-29A6A45F74CF",
"name_form_strength": "Pegasys inj, oppl 180 mikrog/sprøyte",
"prescription_group": "C"
}See everything about peginterferon alfa-2a.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.